Parabolic Drugs (Delisted) share news and announcements
BSE: 533211Pharmaceuticals & Biotechnology
Last traded ₹5.50 on 25 Jan 2021
Delisted on 11 Aug 2021.
Parabolic Drugs disputes and clarifications
46 filed, newest first.
Dec 2020
Nov 2020
17 Nov · Legal
Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Statement of Cash Flow not submitted The response of the Company is awaited.2 Nov · Legal
Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted. -2. Board meeting notice not submitted. The response of the Company is awaited.
Oct 2020
Jul 2020
27 Jul · Legal
Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone audited report not submitted. -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jun 2019
4 Jun · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone audited report not submitted. -2. No Segment Reporting. -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2019
19 Feb · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Board meeting notice not submitted. The response of the Company is awaited.
Jan 2019
Dec 2018
20 Dec · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 17-Dec-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment) 2. Date of appointment/cessation (as applicable) & term of appointment The response of the Company is awaited.
Nov 2018
20 Nov · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is awaited.
Oct 2018
22 Oct · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 19-Oct-2018, regarding " Parabolic Drugs Limited has informed the Exchange that Intimation regarding change of IRP and appointment of RP in the matter of Corporate Insolvency Resolution Process (CIRP) Of Parabolic Drugs Limited.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified 3. Approval of resolution plan by the Tribunal or rejection, if applicable 4. Filing of resolution plan with the Tribunal 5. Number of resolution plan with the Tribunal 6. Brief particulars of invitation of resolution plans under section 25(2)(h) of Insolvency Code in the Form specified under regulation 36A(5) of IBBI (Insolvency Resolution Process for Corporate Persons) Regulations,2016 7. Prior or post-facto intimation of the meetings of Committee of Creditors 8. Appointment/Replacement of the Resolutions Professional 9. List of creditors as required to be displayed by the corporate debtor under regulation 13(2)(c) of the IBBI (Insolvency Resolution process for Corporate Persons ) Regulations.2016 10. Public announcement made pursuant to order passed by the Tribunal under section 13 of Insolvency Code 11. Admission of application by the Tribunal, along with amount of default or rejection or withdrawal, as applicable 12. Filing of application by financial creditors for initiation of CIRP against the corporate debtor, also specifying the amount of default 13. Filing of application by financial creditors for initiation of CIRP also specifying the amount of default The response of the Company is awaited.
Aug 2018
21 Aug · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 14-Aug-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on August 14, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
Jun 2018
May 2018
31 May · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Consolidated Reconciliation of profit and loss not submitted -5. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.30 May · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2018, regarding regarding Board meeting held on May 29, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Feb 2018
19 Feb · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 13-Feb-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2018.This is to inform you that the Board of Directors in its Meeting held on 13th February, 2018 and concluded at 05:10 p.m. :1. Approved the Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2017.2. This is to inform you that Mr. Ashok Kumar Jindal, Chief Financial Officer and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.3. The Company is in the process of appointing a Company Secretary who will act as the Compliance Officer of the Company. In the meantime, Mr. Pranav Gupta (Managing Director) shall act as Compliance Officer pursuant to the SEBI Listing Regulation.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
Dec 2017
20 Dec · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 20-Dec-2017, regarding Outcome of Board Meeting held on December 20, 2017.This is to inform you that the Board of Directors in its Meeting held on 20th December, 2017 and concluded at 03:15 p.m. : 1. This is to inform you that Ms. Ishrat Gill, Company Secretary and Compliance Officer of the Company has resigned from the service of the Company to pursue future career objectives.1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.
Nov 2017
15 Nov · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Reconciliation of profit and loss not submitted -2. Reconciliation of Equity not submitted The response of the Company is awaited.
Oct 2017
23 Oct · Legal
23 Oct · Legal
The exchange asked on 23 Oct 2017
23 Oct · Legal
Exchange has sought clarification from Parabolic Drugs Ltd on October 23, 2017, with reference to increase in Price. The reply is awaited.
Aug 2017
May 2017
30 May · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2017, regarding Outcome of Board Meeting held on May 29, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.11 May · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 10-May-2017, regarding "Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Nov 2016
15 Nov · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 12-Nov-2016, regarding "Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 12, 2016: Inter alia.1) To take note of the resignation of Chief Financial Officer, Mr. Sandeep Sharma of the company.".On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.
Oct 2016
19 Oct · Legal
19 Oct · Legal
The exchange asked on 18 Oct 2016
19 Oct · Legal
Exchange has sought clarification from Parabolic Drugs Ltd on October 19, 2016, with reference to increase in Price. The reply is awaited.
Aug 2016
18 Aug · Legal
Exchange had sought clariification from Parabolic Drugs Limited with respect to an announcement submitted to the Exchange dated August 13, 2016, regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016 wherein board has appointed Mr. Sandeep Sharma, as Chief Financial Officer of the Company.On basis of above, The Company has clarified that :"1. Mr. Sandeep Sharma was appointed as Chief Financial officer of the Company w.e.f. 13-08-2016. 2. There is no relationship between Mr. Sandeep Sharma and any of the Director of the Company. 3. Brief profile of Mr. Sandeep Sharma :With a backup of Chartered Accountant & B.com qualification, have a good knowledge of the various finance functions, financial and accounting policies, principles and procedures, various corporate laws and procedures and statutory enactments.".16 Aug · Legal
Exchange has sought clarification from Parabolic Drugs Limited with respect to an announcement submitted to the Exchange dated August 13, 2016, regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016 wherein board has appointed Mr. Sandeep Sharma, as Chief Financial Officer of the Company.On basis of above Company are required to clarify following -1. Date of appointment/cessation (as applicable) & term of appointment;2. Disclosure of relationships between directors (in case of appointment of a director).3. Brief profile (in case of appointment);The response of the Company is awaited.
Apr 2015
6 Apr · Legal
With reference to the Increase in price, Parabolic Drugs Ltd has Clarified to BSE as under: "As on date, their exists no information as is required to be furnished to the Stock Exchange ....6 Apr · Legal
Price movement : Significant price movement has been observed in Parabolic Drugs Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has vide its letter inter-alia stated, "We have to submit that as on date, there exists no information as is required to be furnished to the Stock Exchange in terms of Clause 36 of the Listing Agreement."6 Apr · Legal
Exchange has sought clarification from Parabolic Drugs Ltd with reference to increase in price on April 6, 2015. The reply is awaited.